NEW YORK – The final analysis of Pfizer’s new Coronavirus vaccine confirms that it is 95-percent effective with no safety concerns.
An independent group monitoring the phase three clinical trial says the vaccine even proved effective in higher risk, older adults.
The 95-percent efficacy rate came after only eight of the thousands of vaccinated patients caught Coronavirus.
162 of the patients in the study who contracted COVID-19 received the placebo.
The only side effect reported from the vaccination was fatigue, which was reported in fewer than four percent of patients after the second dose.
Pfizer and its collaborator BioNTech will seek emergency use authorization from the FDA within days.